Effect of thalidomide on endotoxin-induced decreases in activity and expression of hepatic cytochrome P450 3A2

Biological and Pharmaceutical Bulletin

Volumn 31, Issue 8, 2008, Pages 1596-1600

  Ueyama, Jun ^a,b   Nadai, Masayuki ^c   Zhao, Ying Lan ^d,e   Kanazawa, Hiroaki ^f   Takagi, Kenji ^a   Kondo, Takaaki ^a   Takagi, Kenzo ^a   Wakusawa, Shinya ^a   Abe, Fumie ^e   Saito, Hiroko ^e   Miyamoto, Ken Ichi ^b   Hasegawa, Takaaki ^e  

^a NAGOYA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^c MEIJO UNIVERSITY   (Japan)

^d SICHUAN UNIVERSITY   (China)

^e AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Cytochrome P450 3A2; Endotoxin; Nitric oxide; Thalidomide; Tumor necrosis factor alpha

Indexed keywords

ALBUMIN; CYTOCHROME P450 3A2; ENDOTOXIN; NITRIC OXIDE; PHENAZONE; PROTEIN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER HISTOLOGY; MALE; MEAN RESIDENCE TIME; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; STATISTICAL ANALYSIS; WESTERN BLOTTING;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOWN-REGULATION; DRUG SYNERGISM; ENDOTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOSUPPRESSIVE AGENTS; LIVER; MALE; MEMBRANE PROTEINS; NITRATES; NITRITES; PHARMACEUTICAL PREPARATIONS; RATS; RATS, WISTAR; SPECTROPHOTOMETRY, ULTRAVIOLET; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 48849085836     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.31.1596     Document Type: Article

References (42)

1. Minamiyama Y., Takemura S., Imaoka S., Funae Y., Tanimoto Y., Inoue M., Pharmacol. Exp. Ther., 283, 1479-1485 (1997).
2. Sewer M. B., Morgan E. T., Biochem. Pharmacol., 54, 729-737 (1997).
3. Morgan E. T., Li-Masters T., Cheng P. Y., Toxicology, 181-182, 207-210 (2002).
4. Ueyama J., Kitaichi K., Nadai M., Iwase M., Tomyo N., Kanazawa H., Suzuki R., Takagi K., Takagi K., Hasegawa T., Eur. J. Pharmacol., 498, 257-265 (2004).
5. Ueyama J., Nadai M., Kanazawa H., Iwase M., Nakayama H., Hashimoto K., Yokoi T., Baba K., Takagi K., Takagi K., Hasegawa T., Eur. J. Pharmacol., 510, 127-134 (2005).
6. Hara H., Adachi T., Mol. Pharmacol., 61, 194-200 (2002).
7. Delaporte E., Renton K. W., Life Sci., 60, 787-796 (1997).
8. Iber H., Chen Q., Cheng P. Y., Morgan E. T., Arch. Biochem. Biophys., 377, 187-194 (2000).
9. Warren G. W., van Ess P. J., Watson A. M., Mattson M. P., Blouin R. A., J. Interferon Cytokine Res., 21, 821-826 (2001).
10. Beigneux A. P., Moser A. H., Shigenaga J. K., Grunfeld C., Feingold K. R., Biochem. Biophys. Res. Commun., 293, 145-149 (2002).
11. D'Amato R. J., Loughnan M. S., Flynn E., Folkman J., Proc. Natl. Acad. Sci. U.S.A., 91, 4082-4085 (1994).
12. Yabu T., Tomimoto H., Taguchi Y., Yamaoka S., Igarashi Y., Okazaki T., Blood, 106, 125-134 (2005).
13. Wettstein A. R., Meagher A. P., Lancet, 350, 1445-1446 (1997).
14. Marriott J. B., Muller G., Dalgleish A. G., Immunol. Today, 20, 538-540 (1999).
15. Hideshima T., Chauhan D., Shima Y., Raje N., Davies F. E., Tai Y. T., Treon S. P., Lin B., Schlossman R. L., Richardson P., Muller G., Stirling D. I., Anderson K. C., Blood, 96, 2943-2950 (2000).
16. Teo S. K., Stirling D. I., Zeldis J. B., Drug Discov. Today, 10, 107-114 (2005).
17. Hashimoto Y., Bioorg. Med. Chem., 10, 461-479 (2002).
18. Hashimoto Y., Mini Rev. Med. Chem., 2, 543-551 (2002).
19. Bartlett J. B., Dredge K., Dalgleish A. G., Nature Rev. Cancer, 4, 314-322 (2004).
20. Kim Y. S., Kim J. S., Jung H. C., Song I. S., Mol. Cells, 17, 210-216 (2004).
21. Zhang Z. L., Liu Z. S., Sun Q., World J. Gastroenterol., 11, 216-220 (2005).
22. Enomoto N., Takei Y., Hirose M., Ikejima K., Miwa H., Kitamura T., Sato N., Gastroenterology, 123, 291-300 (2002).
23. Enomoto N., Takei Y., Hirose M., Kitamura T., Ikejima K., Sato N., Alcohol Clin. Exp. Res., 27, 2S-6S (2003).
24. Schmidt H., Rush B., Simonian G., Murphy T., Hsieh J., Condon M., J. Surg. Res., 63, 143-146 (1996).
25. Giamarellos-Bourboulis E. J., Poulaki H., Kostomitsopoulos N., Dontas I., Perrea D., Karayannacos P. E., Giamarellou H., Antimicrob. Agents Chemother., 47, 2445-2449 (2003).
26. Shimazawa R., Sano H., Tanatani A., Miyachi H., Hashimoto Y., Chem. Pharm. Bull., 52, 498-499 (2004).
27. Enomoto N., Takei Y., Hirose M., Ikejima K., Kitamura T., Sato N., Comp. Hepatol., 3, S37 (2004).
28. Soucek P., Gut I., Xenobiotica, 22, 83-103 (1992).
29. Nadai M., Sekido T., Matsuda I., Wang L., Kitaichi K., Itoh A., Nabeshima T., Hasegawa T., J. Pharm. Pharmacol., 50, 871-879 (1998).
30. Omura T., Sato R., J. Biol. Chem., 239, 2370-2378 (1964).
31. Moreira A. L., Sampaio E. P., Zmuidzinas A., Frindt P., Smith K. A., Kaplan G., J. Exp. Med., 177, 1675-1680 (1993).
32. Waxman D. J., Biochem. Pharmacol., 37, 71-84 (1988).
33. Sewer M. B., Morgan E. T., J. Pharmacol. Exp. Ther., 287, 352-358 (1998).
34. Takemura S., Minamiyama Y., Imaoka S., Funae Y., Hirohashi K., Inoue M., J. Hepatol., 30, 1035-1044 (1999).
35. Sampaio E. P., Sarno E. N., Galilly R., Cohn Z. A., Kaplan G., J. Exp. Med., 173, 699-703 (1991).
36. Watanabe N., Suzuki J., Kobayashi Y., J. Biochem. (Tokyo), 120, 1190-1195 (1996).
37. Fernández-Martínez E., Morales-Ríos M. S., Pérez-Álvarez V., Muriel P., Biochem. Pharmacol., 68, 1321-1329 (2004).
38. Shannon E., Noveck R., Sandoval F., Kamath B., Kearney M., Transl. Res., 150, 275-280 (2007).
39. Chen Y. L., Florentin I., Batt A. M., Ferrari L., Giroud J. P., Chauvelot-Moachon L., Biochem. Pharmacol., 44, 137-148 (1992).
40. Morgan E. T., Thomas K. B., Swanson R., Vales T., Hwang J., Wright K., Biochim. Biophys. Acta, 1219, 475-483 (1994).
41. Tinel M., Elkahwaji J., Robin M. A., Fardel N., Descatoire V., Haouzi D., Berson A., Pessayre D., J. Pharmacol. Exp. Ther., 289, 649-655 (1999).
42. Iber H., Li-Masters T., Chen Q., Yu S., Morgan E. T., J. Pharmacol. Exp. Ther., 297, 174-180 (2001).